Cytokinetics Inc (CYTK)

11.70
0.55 4.90
NASDAQ : Health Care
Prev Close 11.15
Open 11.25
Day Low/High 11.10 / 11.40
52 Wk Low/High 5.90 / 13.18
Volume 10.11K
Avg Volume 337.40K
Exchange NASDAQ
Shares Outstanding 40.52M
Market Cap 453.79M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cytokinetics Stock Sees Short Interest Decline 11%

Cytokinetics Stock Sees Short Interest Decline 11%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 387,607 share decrease in total short interest for Cytokinetics Inc , to 3,108,691, a decrease of 11.09% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cytokinetics Announces Publication Relating To Novel Smooth Muscle Myosin Inhibitor

Cytokinetics Announces Publication Relating To Novel Smooth Muscle Myosin Inhibitor

Discovery of Novel Binding Mechanism Has Potential to Guide Design of Myosin Inhibitors

First Week of May 2017 Options Trading For Cytokinetics (CYTK)

First Week of May 2017 Options Trading For Cytokinetics (CYTK)

Investors in Cytokinetics Inc saw new options begin trading this week, for the May 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 200 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Cytokinetics Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv

Cytokinetics Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv

Eligible Patients Have Completed Participation in Phase 3 Clinical Trial VITALITY-ALS

Commit To Buy Cytokinetics At $7, Earn 12.4% Annualized Using Options

Commit To Buy Cytokinetics At $7, Earn 12.4% Annualized Using Options

Investors eyeing a purchase of Cytokinetics Inc shares, but cautious about paying the going market price of $9.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $7 strike, which has a bid at the time of this writing of 55 cents.

Cytokinetics Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas

Cytokinetics Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas

Clearance Triggers $65 Million Upfront Cash Payment in Addition to $30 Million in Sponsored Research & Development Funding Through 2017

Short Interest Drops 28.6% For CYTK

Short Interest Drops 28.6% For CYTK

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,457,024 share decrease in total short interest for Cytokinetics Inc , to 3,640,233, a decrease of 28.58% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cytokinetics Announces Presentation Of Additional Results From COSMIC-HF At The HFSA Annual Scientific Meeting

Cytokinetics Announces Presentation Of Additional Results From COSMIC-HF At The HFSA Annual Scientific Meeting

Data Show Treatment with Omecamtiv Mecarbil May Improve Patient Symptoms at 20 Weeks

Cytokinetics Enters Oversold Territory (CYTK)

Cytokinetics Enters Oversold Territory (CYTK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Will Cytokinetics (CYTK) Stock Be Helped by Cardiovascular Drug Advancement?

Will Cytokinetics (CYTK) Stock Be Helped by Cardiovascular Drug Advancement?

Cytokinetics (CYTK) announced Thursday that its cardiac myosin activator drug has been advanced to phase III clinical development.

Cytokinetics And Amgen To Advance Omecamtiv Mecarbil To Phase 3 Clinical Development

Cytokinetics And Amgen To Advance Omecamtiv Mecarbil To Phase 3 Clinical Development

Company Expects the Initiation of Phase 3 Cardiovascular Outcomes Clinical Trial in Q4 2016

Cytokinetics Completes Enrollment In VITALITY-ALS, Phase 3 Clinical Trial Of Tirasemtiv In Patients With ALS

Cytokinetics Completes Enrollment In VITALITY-ALS, Phase 3 Clinical Trial Of Tirasemtiv In Patients With ALS

Results Expected 2H 2017; Open-Label Extension Trial to Begin in Q4 2016

Cytokinetics (CYTK) Is Strong On High Volume Today

Cytokinetics (CYTK) Is Strong On High Volume Today

Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate

Cytokinetics And Astellas Announce Option Right For Tirasemtiv And Expansion Of Global Collaboration For CK-2127107 In ALS

Cytokinetics And Astellas Announce Option Right For Tirasemtiv And Expansion Of Global Collaboration For CK-2127107 In ALS

Cytokinetics to Receive $65 Million in Upfront Payments and $30 Million in Additional Sponsored R&D; Potential for More than $100 Million in Payments Associated with the Exercise of the Option

Cytokinetics (CYTK) Strong On High Relative Volume Today

Cytokinetics (CYTK) Strong On High Relative Volume Today

Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate